Yet another company that’s hungry for some of Medtronic Infuse’s shrinking slice of the bone graft substitute pie is raising money to commercialize its technology in the U.S. Cerapedics Inc., developer of a biologic bone growth material for use in patients undergoing posterior lumbar interbody fusion spine procedures, has secured $3 million in funding. Its i-Factor Putty is being evaluated in the U.S. as part of an investigational device exemption (IDE) clinical study in the cervical spine, according to a November press release.
